Multimedia Assets Now Available:  FDA Approves Eisai's LENVIMAâ¢ (lenvatinib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Radioactive Iodine-Refractory Differentiated Thyroid Cancer